Eledon Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was $177.41 Mil.
During the past 12 months, Eledon Pharmaceuticals's average Total Assets Growth Rate was -0.20% per year.
During the past 3 years, the average Total Assets Growth Rate was -22.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 75.70% per year.
During the past 10 years, the average Total Assets Growth Rate was 63.80% per year.
During the past 13 years, Eledon Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 184.40%. The lowest was -44.20%. And the median was 145.60%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Eledon Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eledon Pharmaceuticals (NAS:ELDN) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Eledon Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Eledon Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELDN has been successfully added to your 